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Report. 
The primary goal of this research is to develop a synthetic 
elastase inhibitor which would be useful for the treatment of human 
emphysema. A variety of structures are being investigated including 
heterocyclic mechanism-based inhibitors and peptide transition state 
analogs. All of the inhibitors are being tested for specificity with 
other cellular proteases such as cathepsin G and the mast cell 
chymotrypsin-like enzymes (chymases). A secondary goal of this 
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research is the extension of any potent inhibitor structures to 
cathepsin G and mast cell chymases. Any promising elastase inhibitors 
will be provided to other investigators for studies in animal models 
of emphysema. This research should lead to a better understanding of 
the active site structures of the serine proteases involved in 
connective tissue turnover, may produce clinically useful drugs for 
the treatment of emphysema and related diseases, is stimulating the 
research of medicinal chemists in pharmaceutical companies, and will 
provide new tools for the in vivo and in vitro study of the role of 
leukocyte and mast cell proteases in variety of physiological 
processes. 
Isocoumarin Mechanism-Based Inhibitors. Much of our recent 
work has been centered around 7-aminoisocoumarins. Substituted 7- 
amino-4-chloroisocoumarins are potent inactivators of HL elastase and 
a number of other serine proteases. In order to increase the 
solubility of these inhibitors or animal studies, we have investigated 
various 7-acylamino derivatives. We discovered that compounds such as 
the 7-glutarylamino and 7-phthaloylamino were more reactive than the 
7-aminoisocoumarin. This led us to investigate other acyl derivatives 
and we found that the most reactive compounds were derivatives were 
the acyl derivative was fairly hydrophobic. Representative inhibition 
constants are listed below and in the table. 
Cl 






HLE, 133000; PPE, 2400  
Cl 
HLE, 49000, PPE, 8000 
C6H5 
,CH 	HN 	 0 
C6H5, ,NH 
SO2 	0 	 ON 
Cl 
HLE, 200000; PPE, 6500 
HN 
OMe 
Inactivation of Serine Proteases by 7-Acylaminoisocoumarins.  
isocoumarin inhibitor 	HLE 	PPE 	Cat G 	ChyT 
3-Me0-4-C1-7-NH2 	 10000 1000 17 110 
7-Acyl derivatives of above 
7-Glutaryl-NH 	 52000 	2700 
7-Phthaloyl-NH 51000 870 
7-PhNH-CO-NH- 	 49000 	8000 
7-Tos-PhGly-NH- 84000 1500 
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0.1 M Hepes, 0.5 M NaC1, pH 7.5, 10 % Me2SO. Second order 
inhibition constants (kobsd/tI]) are in units of M- ls -1 . HLE = human 
leukocyte elastase, PPE = porcine pancreatic elastase, Cat G = 
cathepsin G, ChyT = chymotrypsin. 
The Tos-Phe-NH derivative is thus far the most reactive of the 
isocoumarin inhibitors. We have spent several days at the laboratory 
of Ed Meyer (Texas A & M) modeling this compound with both PP and HL 
elastase and have not yet come up with a unique binding mode. Ed 
Meyer is planning to do crystallography on several of the isocoumarins 
to determine the structures of the inhibitors bound to PP elastase. 
The proposed inactivation mechanism for isocoumarin inhibitors 
involves acylation of the active site serine by the isocoumarin 
carbonyl. Enzyme acylation is followed by formation of a 4-quinone 
imine methide which can react with an enzyme nucleophile (probably 
His-57) to give an irreversibly inhibited enzyme structure or with a 
solvent nucleophile such as acetate to give a stable acyl enzyme. 
Another isocoumarin structure which is very reactive with HL 
elastase is 7-guanidino-4-chloro-3-methoxyisocoumarin. This is quite 
surprising since HL elastase doesn't hydrolyze substrates with basic 
side chains. However, Wolfram Bode (Munich) has recently solved the 
structure of HL elastase and finds that the Si pocket contains an Asp 
residue (Asp 229). Although this residue points away from the 
substrate it may account for the fact that the 7-guanidino isocoumarin 
is more reactive than expected. Interestingly, cathepsin G has a Glu 
residue at this position. 
Does this react with 
Asp-229 of HL elastase 
 
 
One of our goals for the next year is to investigate the 
significance of these acidic residues in the Si pockets of HL elastase 
and cathepsin G using synthetic substrates and inhibitors. 
Transition State Inhibitors. Peptide aldehydes, peptide 
trifluoromethyl ketones, and peptide boronic acids are three types of 
transition state analogs which have been reported as potent serine 
protease inhibitors. In the enzyme-inhibitor complex, the active site 
serine has added to the aldehyde, ketone or boronic acid moiety to 
form a tetrahedral-like adduct. 
We have recently synthesized the trifluoromethyl ketone shown 
below and find that it is a moderate inhibitor of HL elastase with a 
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K 1 value of 40 .LM. This inhibitor structure was based on the finding 
that the Tos-Phe derivative of the isocoumarin was an excellent 
inhibitor. We simply placed the trifluoromethylketone moiety in the 
location of the isocoumarin carbonyl group. The proposed mechanism of 
inhibition is shown below. We expect that the carbonyl group is 







   
Tos-Phe — NH 
CF3 Tos-Phe — NH 
A specific aim for next year is to make analogs of this structure 
in order to increase its potency. In particular, placement of a 
methyl group on the ring adjacent to the trifluoromethyl ketone should 
interact with the Si pocket and improve the inhibitory potency. 
Specific Objectives. We have several objectives for next 
year. We plan to use molecular modeling of the active sites of HL 
elastase and PP elastase for the improvement of our isocoumarin 
inhibitors and for the design of new types inhibitors. We have 
recently obtained the coordinates for the active site of HL elastase 
and are one of only two groups in the U.S. that have them available at 
present. Based on the crystal structure of HL elastase, we plan to 
investigate the role of Asp 229 in the Si binding pocket on the 
interaction of substrates and inhibitors with HL elastase. We plan to 
synthesize a number of aromatic trifluoromethyl ketone inhibitor 
structures in order to improve their inhibitory potency. We are 
trying to extend the aminoisocoumarin inhibition to simpler 
heterocyclic compounds and are trying to synthesize some oxazoles 
which may also be potent inhibitors. And finally, we plan mechanistic 
studies of the mode of inhibition of some of the inhibitors. These 
will include both C-13 NMR investigations and careful measurement of 
inhibitor deacylation rates. Mechanistic information is extremely 
valuable in the design of the next generation of inhibitors. 
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